Fingolimod recommended by NICE as an option for MS

NICE has approved fingolimod (Gilenya), the first oral treatment for patients with highly active relapsing-remitting multiple sclerosis.

Gilenya (fingolimod) was rejected by the SMC earlier this year
Gilenya (fingolimod) was rejected by the SMC earlier this year
Fingolimod (Gilenya), the first licensed sphingosine 1-phosphate receptor modulator, may be prescribed on the NHS for patients with an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta. However, the manufacturer must provide fingolimod with the discount agreed as part of the patient access scheme.

Safety concerns

The MHRA recently published updated monitoring advice for fingolimod following reports of sudden cardiac death after the initial dose.

Guidance summary

NICE guidance on fingolimod

Further information

View Gilenya drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.

Researchers query safety of delaying antibiotics for UTI in elderly

Researchers query safety of delaying antibiotics for UTI in elderly

Delaying or withholding antibiotics for symptoms of...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.